Xanelim BLA filing
Executive Summary
Genentech and Xoma will conduct an additional pharmacokinetics study to confirm equivalence between Xanelim (efalizumab) material used for clinical testing and commercial lots. The trial will delay the estimated BLA filing date until summer 2002. Genentech had planned to file a BLA in the first quarter of 2002 (1"The Pink Sheet" Aug. 6, p. 20)
You may also be interested in...
Genentech Xanelim Therapy Transition Study To Support Product Launch
Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.
Genentech Xanelim Therapy Transition Study To Support Product Launch
Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.
Genentech Considers Xanelim Chronic Psoriasis Therapy Indication
Genentech hopes to position Xanelim for use as a chronic therapy for moderate to severe plaque psoriasis based on six-month data.